Allegro, Senju collaborate on integrin peptide therapy

May 15, 2013

Allegro Ophthalmics LLC and Senju Pharmaceutical Co. Ltd. have entered into a collaboration and agreement to develop and market Allegro’s integrin peptide therapy in Japan.

 

San Juan Capistrano, CA and Osaka, Japan-Allegro Ophthalmics LLC and Senju Pharmaceutical Co. Ltd. have entered into a collaboration and agreement to develop and market Allegro’s integrin peptide therapy in Japan.

With this collaboration, the companies aim to improve the quality of life for patients who continue to be at risk of blindness from vascular eye diseases by establishing integrin peptide therapy as the first‐in‐class treatment targeting integrin with an oligopeptide.

Under the terms of the agreement, Senju will acquire the rights to co‐develop and market Allegro’s integrin peptide therapy in Japan. In exchange for these rights, Senju has agreed to pay Allegro an upfront license fee, additional development and sales milestone fees, and a percentage royalty on net sales.

“The announcement of this partnership with Allegro further evidences Senju’s commitment to its position as a leader in ophthalmology in Japan,” said Shuhei Yoshida, executive vice president of Senju Pharmaceutical. “We believe that Allegro’s integrin peptide therapy shows great promise as a first‐in‐class treatment for wet age-related macular degeneration, diabetic macular edema, and other vascular eye indications, and we are eager to begin the process for regulatory approval in Japan.”

For more articles in this issue of Ophthalmology Times eReport, click here.